期刊文献+

UGT2B7基因多态性对丙戊酸血药浓度的影响(英文) 被引量:8

Effect of UGT2B7 genetic variants on serum valproic acid concentration
下载PDF
导出
摘要 目的:探讨UGT2B7 A268G和UGT2B7 G211T基因多态性对丙戊酸血药浓度的影响。方法:用限制性片段长度多态性聚合酶链反应(polymerase chain reaction restriction fragment length polymorphism,PCR-RFLP)的方法分别对248名癫痫患者检测UGT2B7 A268G和UGT2B7 G211T两个位点的基因型,并收集患者的基本流行性病学资料和相关临床信息,如癫痫类型、病史、服药剂量、疗效和肝肾功能等。采用SPSS 13.0软件分别对资料进行多元线性回归、单因素方差分析、卡方检验和配对T检验等方法的数据统计。结果:多元线性回归分析显示,性别、年龄和体质量指数与丙戊酸血药浓度无明显相关,而浓度剂量比率则与血药浓度相关。在被纳入的248名患者中,UGT2B7 A268G和UGT2B7 G211T的基因型均符合哈迪温伯格平衡定律。UGT2B7-268A等位基因频率为30.05%,而G等位基因频率为69.95%,且携带AA,AG,GG不同基因型的患者服用丙戊酸后血药浓度的比较差异有统计学意义(F=5.477,P=0.005),AA基因组显著高于GG基因组(P=0.048),其他两组间比较差异无统计学意义(P>0.05).UGT2B7 211G等位基因频率为77.24%,T等位基因频率为22.58%;而携带该位点GG,GT和T不同基因型的患者服用丙戊酸后,三者血药浓度间比较,差异无统计学意义(P>0.05)。结论:本研究揭示了UGT2B7A268G和UGT2B7G211T的基因多态在中国汉族癫痫人群中的分布,UGT2B7 A268G基因多态参与体内丙戊酸代谢并进而影响其血药浓度。临床上针对癫痫患者给予丙戊酸药物时,需要考虑患者携带UGT2B7A268G位所产生的影响而适当调整患者用药剂量。 Objective: To investigate the effect of UGT2B7 A268G and UGT2B7 G211T genetic polymorphism on serum drug concentration ofvalproic acid (VPA). Methods: Genetic polymorphisms of UGT2B7 A268G and UGT2B7 G211T were tested in 248 epileptic patients by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Data including basic information, epilepsy type, times and doses of drug, treatment response and liver and kidney functions were collected. Statistical analysis was performed by SPSS 13.0 through multivariate linear regression, one-way ANOVA, X2 test, and paired T-test. Results: Based on multivariate linear regression, there was no significant difference between gender, age, or body mass index and VPA, but concentration-to-dose ratios (CDRs) were positively correlated with VPA. The genetic polymorphisms of UGT2B7 A268G and UGT2B7 G211T were consistent with Hardy-Weinberg equilibrium. UGT2B7-268A 〉 G allele frequency distribution A was 30.05%, and G was 69.95%. Variance analysis showed that serum drug concentration was significantly different in the genotype ofAA, AG, or GG (F=5.477, P=0.005). Further analysis of paired T test showed that AA type was significantly different from GG type (P=0.048), and that serum concentration of AA type was much higher than that of GG type, while no significant difference between AA type and AG type, GG type and AG type. UGT2B7 G211T allele frequency distribution G was 77.24%, and T was 22.58%. q-here was no significant difference in standardized serum concentration among genotypes of GG, GT, and TF. Conclusion: This study reveals UGT2B7 A268G genetic polymorphism distribution in Chinese epilepsy population. UGT2B7 A268G plays an important role in VPA's metabolism, and has certain effect on VPA's serum concentration. Epilepsy patient with this genotype should be adjusted the dose of VPA to make a therapeutic effect.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2013年第8期766-772,共7页 Journal of Central South University :Medical Science
基金 supported by the Natural Science Foundation of Hunan Province,P.R.China(11JJ5064)
关键词 UGT 基因多态性 丙戊酸 癫痫 UGT genetic polymorphism valproic acid epilepsy
  • 相关文献

参考文献18

  • 1Hung CC, Ho JL, Chang WL, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization[J]. Pharmacogenomics, 2011, 12(8): 1107-1117.
  • 2Downing C, Biers J, Larson C, et al. Genetic and maternal effects on valproic acid teratogenesis in C57BL/6J and DBA/2J mice[J]. Toxicol Sci, 2010, 116(2): 632-639.
  • 3Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs[J]. Curr Opin Neurol, 2009, 22(2): 144-149.
  • 4Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- gluoamnosyltransferases [ J]. Biochem Pharmacol, 2003, 65(9): 1441-1449.
  • 5Soars MG, Smith DJ, Riley RJ, et al. Cloning and characterization of a canine UDP-glucuronosyltransferase[J]. Arch Biochem Biophys, 2001, 391(2): 218-224.
  • 6Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGTI gene family[J ]. Drug Metab Dispos, 1993, 21 (1): 50-55.
  • 7Jin C, Miners JO, Lillywhite KJ, et aI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate- glucuronosyltransferase glucuronidating carboxylic acid-containing drugs [J]. J Pharmacol Exp Ther, 1993, 264(1): 475-479.
  • 8Makmor-Bakry M, Sills GJ, Hitiris N, et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing[J]. Clin Neuropharmacol, 2009, 32(4): 205-212.
  • 9王艳,高丽,刘艳萍,黄楠楠,许淑静,马冬菊.河南汉族癫癎儿童UGT1A6 A541G基因多态性与丙戊酸血药浓度相关性研究[J].中国当代儿科杂志,2010,12(6):429-432. 被引量:10
  • 10Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy[J]. Drug Metab Dispos, 2003, 31 (S): 677-680.

二级参考文献18

  • 1Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovie J, Baker R (2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Prac- titioners, http ://www. nice. org. uk/.
  • 2Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodrlguez I. Valproic acid clearance in children with epilepsy [J]. Clin Pharm Ther, 1998, 23(1) :31-34.
  • 3von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V co allele) on doseadjusted eyclosporin Atrough ncentrations or rejection incidence in stable renal transplant recipients [ J]. Clin Chem, 2001,47 (6) : 1048-1052.
  • 4Nagar S, Zalatoris JJ, Blanehard RL. Human UGT1 A6 pharmacogenetics : identication of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells [ J ]. Pharmacogeneties, 2004, 14(8) :487-499.
  • 5Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases [ J ]. Biochem Pharmacol, 2003, 65 ( 9 ) : 1441-1449.
  • 6Yamagata T, Momoi MY, Mural K, Ikematsu K, Suwa K, Sakamoto K, et al. Penipenem-betamipron and decreases in serum valproic acid concentration [ J ]. Ther Drug Monit, 1998, 20 (4) : 396-400.
  • 7Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferase: metabolism, expression, and disease [ J ]. Annu Rev Pharmacol Toxicol, 2000, 40:581-616.
  • 8Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M, et al. Linkage disequilibrium of UGT1A1 * 6 and 15GT1A1 * 28 in relation to UGT1A6 and UGT1A7 polymorphisms [ J]. Oncol Rep, 2006, 16(4) :801-806.
  • 9Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1 A6 (planar phenol) UDP-glucuronosyl -transferase: pharmacological implications [ J ]. Pharmacogenetics, 1997, 7(6) :485-495.
  • 10Nagar S, Zalatoris J, Blanchard R. Human UGT1 A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells [ J ]. Pharmacogenetics, 2004, 14(8) :487-499.

共引文献9

同被引文献71

引证文献8

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部